GLP-1 weight-loss drugs: eating less may mean shortfalls in fibre, vitamin D and iron
An exploratory study published on 17 November 2026 in BMJ Nutrition, Prevention & Health suggests that some people treated with GLP-1-based obesity drugs, such as semaglutide (Wegovy) and tirzepatide (Mounjaro), may cut their food intake so far that they no longer meet their needs for certain nutrients, often without noticing.
Background
GLP-1 receptor agonists (and dual GIP/GLP-1 agonists such as tirzepatide) reduce appetite and slow gastric emptying: people eat less and lose weight. That is the intended effect. The open question is the quality of what remains on the plate: with very small portions it becomes harder to get enough fibre, vitamins and minerals.
After bariatric surgery, nutritional follow-up with blood tests and dietitian support is standard practice. For GLP-1 drugs, the authors note, no specific nutritional monitoring pathway exists yet.
The study
• Carried out by University of Oxford medical students (first author Dhanush Ammineni) together with a general practice in Northamptonshire, England
• Of 97 patients invited, 14 completed the study: 11 women and 3 men, aged 27 to 73; 12 were taking tirzepatide
• Each participant kept a validated online food diary (myfood24) for two days
• Intake of 28 nutrients was compared with UK reference values; a shortfall was defined as intake below two-thirds of the recommended amount
• The analysis focused on six nutrients: fibre, iron, vitamin D, potassium, protein and magnesium
• Each participant also had a telephone interview about their experience with the drug
Results
• Half of the participants ate less than about 1,230 kcal a day; intakes ranged from 541 to 2,312 kcal, and three people were below 800 kcal
• Fibre was insufficient in 12 of 14 people, dietary vitamin D in 11 and iron in 7
• Eight participants fell short on at least three of the six focus nutrients; one person on all six
• No one reached five portions (400 g) of fruit and vegetables a day
• Protein, by contrast, was adequate in almost everyone: only one participant ate too little
• Two people said they were surprised and worried to discover, through the diary, how little they were eating; many reported receiving little dietary guidance after starting treatment
The finding fits an established picture: an earlier analysis of more than 461,000 adults starting a GLP-1 drug recorded a diagnosis of nutritional deficiency in almost 13% within six months and in more than 22% within a year.
What it means for laboratory testing
The study measured what people ate, not blood levels: a low intake is not the same as a confirmed deficiency. Laboratory tests are needed to know whether a deficiency is really present. The most relevant tests for the nutrients highlighted by the study are:
• Vitamin D (25-OH vitamin D), bearing in mind that most vitamin D is made in sun-exposed skin rather than obtained from food
• Ferritin, serum iron and transferrin to assess iron stores, together with a complete blood count to detect possible anaemia
• Magnesium and potassium, also useful in case of nausea, vomiting or diarrhoea, which are common side effects of these drugs
• Albumin as a general marker of nutritional status
• Vitamin B12 and folic acid, when the diet is very limited or not varied
Which tests to do, and when, is a decision to make with the doctor who manages the treatment.
Who it concerns
• People who use, or are about to start, a GLP-1 drug for obesity or diabetes, especially if they eat very little or skip meals
• People already at risk of deficiencies: women of reproductive age (iron), older adults, those on very restrictive diets
• GPs, diabetologists and nutrition professionals who prescribe or follow these treatments
Limitations
• The study is very small (14 people) and took place in a single practice, in a relatively affluent area, with volunteer patients who were mostly women
• Each person recorded only two days of self-reported eating
• There are no data on diet before treatment: the shortfalls cannot be attributed to the drug
• No blood tests were performed, so no actual deficiency was confirmed
• The authors describe it as exploratory and propose a larger study of about 120 patients across several practices
In summary
• On GLP-1 drugs people eat less, and in some of them intake of fibre, vitamin D and iron drops below recommended levels
• Protein, in this small group, was almost always adequate
• The data come from 14 patients and food diaries, not blood tests: larger studies are needed
• The practical message is attention to diet and, when the doctor considers it useful, checking with laboratory tests
Sources:
BMJ Nutrition, Prevention & Health (17 November 2026); BMJ Group press release (Scimex); Medical Xpress; HealthDay / U.S. News
Laboratory tests:
Vitamina D, Ferritina, Sideremia, Transferrina, Emocromo, Magnesio, Potassio, Albumina, Vitamina B12, Acido folico, Zinco
Diseases, symptoms and related pages:
Farmaci per dimagrire, Semaglutide Wegovy Obesità, Retatrutide e obesità, Obesità, Anemia, Osteoporosi, Dieta e osteoporosi, Dieta Mediterranea, Check-Up Completo













































Discussion about this post